Topical Aminolevulinic Acid HCl Photodynamic Therapy
Authors:
- 1 March 2000
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 1 (2) , 133-139
Abstract
▴ Photodynamic therapy (PDT) is the treatment of tumors or dysplasic tissue with drugs that produce cytotoxic metabolites when exposed to light. ▴ Aminolevulinic acid HCl (5-aminolevulinic acid HCl; ALA) is a prodrug that is metabolized intracellularly to form the photosensitizing molecule protoporphyrin (PpIX). When PpIX is activated by light, cytotoxic reactive oxygen species and free radicals are generated. ▴ ALA can diffuse through skin and preferentially localizes in tumors and dysplasic tissue; subsequent exposure of PpIX-loaded tumor cells to light can destroy the tumor. ▴ After application of a 20% solution of ALA to actinic keratosis lesions of the head, PpIX (as measured by skin fluorescence) peaked 11 hours after treatment and the mean clearance half-life was 30 hours. ▴ In phase II trials 10 J/cm2 of blue light (wavelength = 417nm) delivered at 10 mW/cm2 for 1000 seconds was found to provide maximal therapeutic effect on lesions of the head after treatment with 20% ALA. ▴ In phase III trials of ALA PDT in 241 patients with lesions of the head 72% of patients had a complete response to treatment at 12 weeks versus 20% of those treated with vehicle and light alone. Some of these patients had been re-treated at 8 weeks. ▴ In these trials 12% of ALA-treated patients and 37.5% of those receiving vehicle whose lesions had cleared at 8 weeks had relapsed at 12 weeks. When the total number of lesions were considered the recurrence rate was 5 and 27.9% for ALA- and vehicle-treated lesions, respectively. ▴ All patients reported some degree of burning or stinging during PDT but this usually subsided after irradiation was completed and was rarely treatment-limiting. Localized erythema and edema were also common. No other significant adverse effects were noted and treatment was generally well tolerated. ▴ A well designed dermal applicator ensured perilesional skin was spared collateral damage.Keywords
This publication has 9 references indexed in Scilit:
- Photodynamic TherapyDrugs & Aging, 1999
- 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administrationJournal of Photochemistry and Photobiology B: Biology, 1998
- Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissuesCancer Letters, 1997
- Development of Malignant Melanoma after Repeated Topical Photodynamic Therapy with 5-Aminolevulinic Acid at the Exposed SiteDermatology, 1997
- Photodynamic Therapy with Topical Application of 5-Aminolevulinic Acid in the Treatment of Actinic Keratoses: An Initial Clinical StudyDermatology, 1996
- Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid applicationCancer Letters, 1995
- New drugs and future developments in photodynamic therapyEuropean Journal of Cancer, 1993
- The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cellsCancer Letters, 1992
- New trends in photobiologyJournal of Photochemistry and Photobiology B: Biology, 1992